Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
$33.30
-$0.03(-0.09%)
At close: 4:00 PM EST
$33.30
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)952.51K
Market Cap
$1.94B
Enterprise Value$1.90B
Total Cash (Recent Filing)$854.42M
Total Debt (Recent Filing)$40.21M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Apr 29, 2026EPS Estimate
-1.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding58,592,170
10 Day Avg. Volume1,283,213
30 Day Avg. Volume952,514
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue35.21
Enterprise Value/Gross Profit39.89
Enterprise Value/Ebitda-4.34
Forecast
1Y Price Target
$41.83Price Target Upside25.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-6.62
Revenue Forecast (FY)$92.32M
Bulls Say, Bears Say
Bulls Say
Commercial Launch UptakeEarly commercial launch of Aqvesme under a liver-monitoring REMS produced initial prescriptions and dispensing, indicating early market acceptance and potential for a revenue ramp with continued physician adoption.
Pipeline Clinical ReadoutsMultiple pipeline candidates, including tebapivat, AG-236, and AG-181, have forthcoming clinical data readouts that could materially alter the company's outlook and investor sentiment.
Regulatory PathwayFDA guidance establishing an accelerated approval pathway for mitapivat in sickle cell disease creates a clear regulatory route that could unlock meaningful stock upside if a submission advances.
Bears Say
Confirmatory Trial Alignment RiskRegulatory submission remains dependent on FDA alignment on the confirmatory trial design, representing a key execution risk that could delay approval prospects.
Phase 3 Endpoint UncertaintyA Phase 3 study met a hemoglobin response but did not reach significance on the pain crisis endpoint, creating uncertainty about relying on that trial alone for full approval.
REMS And Reimbursement DelaysREMS certification, required liver testing, and prior authorization procedures are expected to create a multi-week lag between prescription generation and revenue recognition, slowing near-term sales realization.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.94B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Apr 29, 2026 which is in 13 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Feb 12, 2026. The company reported -$1.86 earnings per share for the quarter, beating the consensus estimate of -$1.954 by $0.094.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.81.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 58,592,170 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.86 in its last earnings report, beating expectations of -$1.954. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.83 (25.62% Upside)
$41.83 (25.62% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.15%
12-Months-Change
Fundamentals
Return on Equity
-31.07%
Trailing 12-Months
Asset Growth
-22.00%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and pipeline momentum: notable Q4 revenue growth (86% YoY), Afesmi U.S. approval and an encouraging early launch (44 prescriptions in five weeks), a robust near-term catalyst calendar, and a healthy balance sheet (~$1.2B). Offsetting risks include near-term revenue timing delays (10–12 week conversion from script to treatment), anticipated sequential U.S. revenue decline into early 2026 due to ordering and inventory dynamics, sizeable R&D/SG&A spend without a specific profitability timetable, and regulatory uncertainty around the sickle cell approval pathway. Overall, the positives (approval, growth, cash runway, and multiple upcoming data readouts) outweigh the operational and timing headwinds, supporting an optimistic outlook.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$41.83
▲(25.62% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
Currently, No data available
---